Biotech Values

[genisi]

GT3 patients will also have the option to be treated with Sofosbuvir/PegRiba until a more viable oral combination is developed.

So, why not try sofo+riba first and those not cured can either wait for a more viable oral combination like sofo+GS-5816 or elect to go with the Sofosbuvir/PegRiba treatment. I think patients, docs and the FDA itself want to get rid of peg-inf and I really don't see anyone trying a non oral interferon containing combo ahead of an oral inf-free one. IMO, if data from all trials show non-inferiority to SoC, then the FDA will approve (perhaps restrict cirrhotic GT3 patients). Even if the FDA will only approve sofo+peg/riba in GT3, I still think we'll see off-label use of the oral combo.